Aileron therapeutics inc (ALRN)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Dec'16
Assets
Current assets:
Cash and cash equivalents

10,697

5,311

6,867

10,157

11,272

10,635

7,716

11,980

6,782

11,863

13,428

9,397

20,715

Investments

1,998

12,967

17,694

21,365

1,998

10,060

20,229

23,811

36,509

38,889

43,437

1,946

0

Prepaid expenses and other current assets

967

1,247

1,911

1,012

1,094

1,055

2,083

1,390

1,067

1,000

1,164

561

333

Restricted cash

25

25

25

25

25

25

25

25

88

88

88

88

25

Total current assets

13,687

19,550

26,497

32,559

14,389

21,775

30,053

37,206

44,446

51,840

58,117

11,992

21,073

Operating lease, right-of-use asset

5,893

6,060

6,224

6,385

6,543

-

-

-

-

-

-

-

-

Property and equipment, net

225

295

361

379

398

7,290

6,832

4,123

134

154

111

109

107

Restricted cash, non-current

568

568

568

568

568

568

568

568

568

-

-

-

63

Other assets

-

-

302

302

501

679

680

680

683

694

808

782

778

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

2,222

-

Total assets

20,373

26,473

33,952

40,193

22,399

30,312

38,133

42,577

45,831

52,688

59,036

15,105

22,021

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

1,088

1,452

2,349

1,719

858

1,731

2,994

1,583

1,796

1,600

1,650

2,212

1,971

Accrued expenses and other current liabilities

4,587

3,941

3,653

3,262

3,378

3,639

4,111

4,781

3,060

3,291

3,373

3,259

2,100

Operating lease liability, current portion

468

446

426

406

387

-

-

-

-

-

-

-

-

Total current liabilities

6,143

5,839

6,428

5,387

4,623

5,370

7,105

6,364

4,856

4,891

5,023

5,471

4,071

Operating lease liability, net of current portion

4,461

4,586

4,708

4,822

4,929

-

-

-

-

-

-

-

-

Construction financing liability

-

-

-

-

-

5,342

4,997

3,345

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

11

Total liabilities

10,604

10,425

11,136

10,209

9,552

10,712

12,102

9,709

4,856

4,891

5,023

5,471

4,082

Commitments and contingencies (Note 9)

-

-

-

-

-

-

0

0

0

-

0

0

0

Redeemable convertible preferred stock (Series A, A-1, B, C-1, C-2, D, D-1, E, E-1, E-2, E-3 and F), $0.01 par value; no shares and 151,557,293 shares authorized at September 30, 2017 and December 31, 2016, respectively; no shares and 105,631,019 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively

-

-

-

-

-

-

-

-

-

-

-

130,412

129,745

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

0

0

0

-

0

-

0

Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2020 and December 31, 2019; 27,810,358 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

28

28

28

28

15

15

15

15

15

15

15

0

-

Additional paid-in capital

214,625

214,148

213,671

213,083

188,811

188,083

187,478

186,890

185,544

184,761

184,085

3,044

2,536

Accumulated other comprehensive gain/(loss)

-1

7

17

24

-

-5

-3

-12

-50

-33

-6

-

-

Accumulated deficit

-204,883

-198,135

-190,900

-183,151

-175,979

-168,493

-161,459

-154,025

-144,534

-136,946

-130,081

-123,822

-114,342

Total stockholders’ equity

9,769

16,048

22,816

29,984

12,847

19,600

26,031

32,868

40,975

47,797

54,013

-120,778

-111,806

Total liabilities and stockholders’ equity

20,373

26,473

33,952

40,193

22,399

30,312

38,133

42,577

45,831

52,688

59,036

15,105

22,021